Stemgent Betting $4.5M on Scottish Biotech

Xconomy Boston — 

Stemgent, a provider of biological materials for life sciences research with offices in Cambridge, MA, and San Diego, reports this morning it will invest $4.5 million over the next three years in the Dundee, Scotland-based biotech firm Ubiquigent. Ubiquigent is producing biological products developed by the Scottish Institute for Cell Signalling at the University of Dundee. Stemgent is handling initial marketing of the fledgling Scottish biotech’s products in the U.S. market.